Biodesix to present data at iaslc 2022 world conference demonstrating that the veristrat® test is predictive of progression free survival and overall survival in patients with low or negative pd-l1 treated with immune checkpoint inhibitors

Boulder, colo.--(business wire)---- $bdsx #patientsfirst--biodesix, inc. (nasdaq: bdsx), a leading data-driven diagnostic solutions company with a focus in lung disease, announced today that young kwang chae, md, mph, mba, associate professor of medicine (hematology and oncology) feinberg school of medicine, northwestern university will present the results of a retrospective analysis at the iaslc 2022 world conference on lung cancer hosted by the international association for the study of lung cancer (#wclc2022) on aug
BDSX Ratings Summary
BDSX Quant Ranking